Lixisenatide Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2027
The global lixisenatide market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lixisenatide is a once-daily injectable GLP-1 receptor agonist. It is sold under the brand name Lyxumia in the European Union and Adlyxin in the US. It is manufactured by Sanofi and is used to treat type 2 diabetes. The major factor driving the demand for lixisenatide is the increasing prevalence of diabetes across the globe.
According to the International
Diabetes Federation (IDF), in 2021, approximately 537 million adults aged 20-79
years has diabetes globally with 3 in 4 adults with diabetes living in low- and
middle-income countries with a mortality rate of 6.7 million people globally.
Additionally, the total number of people living with diabetes is anticipated to
rise to 643 million by 2030 and 783 million by 2045. Moreover, almost 1 in 2
(240 million) adults living with diabetes are undiagnosed. Hence, the rising
prevalence of diabetes is encouraging the demand for lixisenatide.
To Request a Sample of our Report on Lixisenatide Market: https://www.omrglobal.com/request-sample/lixisenatide-market
Some major players in the market include Zealand Pharma A/S
and Sanofi SA, among others. The market players are contributing significantly
to the growth of the market by the adoption of various strategies including
mergers & acquisitions, geographical expansion, partnerships and
collaborations, and new product launches, to stay competitive in the market.
For instance, in October 2019, Sanofi announced the launch of Suliqua (insulin
glargine/lixisenatide) in the UK. The drug is a once-daily, titratable,
fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1
receptor agonist lixisenatide used to treat type 2 diabetes in adults.
Market Coverage
•
The market number available for – 2020-2027
•
Base year- 2020
•
Forecast period- 2021-2027
Segment Covered-
•
By Product
•
By Type of Manufacturing
•
By End-User
Regions Covered-
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World
Competitive Landscape- Zealand Pharma A/S, and Sanofi
SA, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Lixisenatide Market is Available @ https://www.omrglobal.com/industry-reports/lixisenatide-market
Global Lixisenatide Market Report by Segment
By Product
• Industrial
Grade
• Pharmaceutical
Grade
By Type of Manufacturing
• In-house
Manufacturing
• Contract
Manufacturing Organizations
Global Lixisenatide Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment